Department of Otolaryngology-Head and Neck Surgery, The University of Western Ontario, London, ON N6A 5W9.
J Otolaryngol Head Neck Surg. 2012 Apr;41(2):124-30.
Early-stage laryngeal squamous cell carcinoma is managed with radiotherapy or endoscopic surgery. Although cure rates are high, radiation failures often require total laryngectomy for salvage. Biomarkers that can predict tumour radioresistance may be useful in modifying the treatment approach for individual patients.
Retrospective patient chart review yielded 75 patients with T1-T2 glottic squamous cell carcinoma treated with radiation therapy at the London Health Sciences Centre. Pretreatment tumour biopsies were immunostained for B-cell lymphoma 2 (Bcl-2), Ki-67, and epidermal growth factor receptor (EGFR) to correlate biomarker expression with disease-free survival (DFS).
Ki-67 expression was strongly associated with recurrence following radiation and independently predicted poor DFS (hazard ratio 4.86, 95% CI 1.58-15.00; p = .006). EGFR and Bcl-2 were not associated with a risk of recurrence.
Ki-67 expression identified a subset of patients with increased risk of local recurrence after radiation therapy. Ki-67 expression can potentially guide improved personalized treatments for patients with early-stage glottic squamous cell carcinomas.
早期喉鳞状细胞癌采用放疗或内镜手术治疗。尽管治愈率很高，但放射治疗失败通常需要全喉切除术进行挽救。预测肿瘤放射抵抗的生物标志物可能有助于为个别患者修改治疗方法。
对伦敦健康科学中心接受放射治疗的 75 例 T1-T2 声门型鳞状细胞癌患者进行回顾性患者病历审查。对治疗前的肿瘤活检进行 B 细胞淋巴瘤 2 （Bcl-2）、Ki-67 和表皮生长因子受体（EGFR）的免疫染色，以将生物标志物表达与无疾病生存（DFS）相关联。
Ki-67 的表达与放射后的复发密切相关，并独立预测了较差的 DFS（危险比 4.86，95%CI 1.58-15.00；p ＝ 0.006）。EGFR 和 Bcl-2 与复发风险无关。
Ki-67 的表达确定了一组放射治疗后局部复发风险增加的患者。Ki-67 表达可能有助于为早期声门型鳞状细胞癌患者提供更个性化的治疗。
